Scarica l'app Stockscreener
53.57
3.20%
1.66
Dopo l'orario di chiusura:
53.57
Precedente Chiudi:
$51.91
Aprire:
$51.33
Volume 24 ore:
3.25M
Relative Volume:
1.36
Capitalizzazione di mercato:
$10.29B
Reddito:
$2.95B
Utile/perdita netta:
$523.88M
Rapporto P/E:
19.91
EPS:
2.69
Flusso di cassa netto:
$620.18M
1 W Prestazione:
-1.67%
1M Prestazione:
-1.09%
6M Prestazione:
-15.89%
1 anno Prestazione:
-18.70%
Intervallo 1D:
$51.00
$53.62
Intervallo di 1 settimana:
$51.00
$56.80
Portata 52W:
$51.00
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Nome
Biomarin Pharmaceutical Inc
Settore
Industria
Telefono
(415) 506-6700
Indirizzo
105 DIGITAL DRIVE, NOVATO, CA
Confronta BMRN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
53.57 | 9.97B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-08 | Iniziato | H.C. Wainwright | Neutral |
| 2025-09-03 | Iniziato | Raymond James | Outperform |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-02-24 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-30 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-20 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Iniziato | Evercore ISI | Outperform |
| 2023-11-15 | Iniziato | Wells Fargo | Overweight |
| 2023-10-23 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Iniziato | Raymond James | Mkt Perform |
| 2023-09-18 | Iniziato | UBS | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-07-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2023-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Iniziato | Citigroup | Neutral |
| 2023-01-30 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2022-10-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Ripresa | Wedbush | Neutral |
| 2022-04-25 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-09-09 | Aggiornamento | Stifel | Hold → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-04 | Ripresa | Guggenheim | Buy |
| 2021-03-01 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Downgrade | Stifel | Buy → Hold |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Reiterato | Citigroup | Buy |
| 2020-01-28 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-27 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-24 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-04-09 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Reiterato | Stifel | Buy |
| 2018-08-03 | Reiterato | Stifel | Buy |
Mostra tutto
Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie
Can BioMarin Pharmaceutical Inc. stock hit analyst price targetsJuly 2025 Outlook & Free Technical Pattern Based Buy Signals - newser.com
Will BioMarin Pharmaceutical Inc. (BM8) stock hit analyst forecastsEarnings Risk Report & Verified Trade Idea Suggestions - newser.com
Exit strategy if you’re trapped in BioMarin Pharmaceutical Inc.July 2025 Fed Impact & Real-Time Market Trend Scan - newser.com
How strong is BioMarin Pharmaceutical Inc. stock balance sheetMarket Growth Summary & Free Fast Gain Swing Trade Alerts - newser.com
BioMarin Pharmaceutical (NASDAQ:BMRN) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat
What is William Blair's Estimate for BMRN Q4 Earnings? - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Purchases 14,700 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Is BioMarin Pharmaceutical Inc. (BM8) stock cheap by valuation metricsJuly 2025 Drop Watch & Free Weekly Watchlist of Top Performers - newser.com
Can BioMarin Pharmaceutical Inc. (BM8) stock reach $200 price targetOptions Play & Weekly Return Optimization Plans - newser.com
Why BioMarin Pharmaceutical Inc. stock is in analyst buy zoneWeekly Trend Report & Safe Capital Growth Stock Tips - newser.com
Why BioMarin Pharmaceutical Inc. stock is seen as undervaluedJobs Report & Free Technical Pattern Based Buy Signals - newser.com
Morgan Stanley Maintains Buy on BioMarin Pharmaceutical (BMRN) - MSN
How to monitor BioMarin Pharmaceutical Inc. with trend dashboards2025 Valuation Update & High Yield Stock Recommendations - newser.com
10 Best Beaten Down Growth Stocks to Buy According to Analysts - Insider Monkey
BioMarin Pharmaceutical (NASDAQ:BMRN) Reaches New 12-Month LowWhat's Next? - MarketBeat
Cantor Fitzgerald Has Negative View of BMRN FY2025 Earnings - MarketBeat
How currency fluctuations impact BioMarin Pharmaceutical Inc. stock2025 Technical Overview & Safe Swing Trade Setups - newser.com
How to read the order book for BioMarin Pharmaceutical Inc.Market Activity Report & Daily Profit Focused Stock Screening - newser.com
Sentiment analysis tools applied to BioMarin Pharmaceutical Inc.Global Markets & AI Enhanced Trading Alerts - newser.com
BioMarin Pharmaceutical (BMRN) Announces Financial Results for Q3 2025 - Insider Monkey
13 Stocks to Buy with Exponential Growth Heading into 2026 - Insider Monkey
BioMarin Pharmaceutical Inc. Just Missed Earnings With A Surprise LossHere Are Analysts Latest Forecasts - Yahoo Finance
Earnings Miss: BioMarin Pharmaceutical Inc. Missed EPS And Analysts Are Revising Their Forecasts - simplywall.st
Biomarin Pharmaceutical stock hits 52-week low at 51.52 USD By Investing.com - Investing.com South Africa
After a futile battle, Biomarin will sell the bleeding disorder drug Roctavian - medwatch.com
Biomarin Pharmaceutical stock hits 52-week low at 51.52 USD - Investing.com
Cantor Fitzgerald Issues Negative Forecast for BMRN Earnings - MarketBeat
BioMarin Pharma plans to divest struggling gene therapy - MSN
Results: BioMarin Pharmaceutical Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts - 富途牛牛
BioMarin Pharmaceutical (NASDAQ:BMRN) Earns Outperform Rating from Wedbush - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Cut to $70.00 by Analysts at Wells Fargo & Company - MarketBeat
Stifel Nicolaus Cuts BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $73.00 - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Lowered to $80.00 at Barclays - MarketBeat
BioMarin (NASDAQ: BMRN) PALYNZIQ sBLA gets FDA Priority Review to expand to ages 12–17 - Stock Titan
HC Wainwright Has Lowered Expectations for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price - MarketBeat
Morgan Stanley Lowers BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $98.00 - MarketBeat
Teacher Retirement System of Texas Increases Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Sumitomo Mitsui Trust Group Inc. Raises Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Asset Management One Co. Ltd. Has $4.84 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Biomarin’s Acquisition Strategy: Navigating Risks and Challenges for Future Growth - TipRanks
Biomarin Pharmaceutical Inc Azioni (BMRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):